Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-Cel) Out-of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
Leukemia
Leukemia
Leukemia
N/A
Oluwole, Olalekan
VICC-CTT25006
Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs SOC in Patients with Recurrent Glioblastoma
Neuro-Oncology
Neuro-Oncology
Neuro-Oncology
II
Mohler, Alexander
NCT06325683
ALLNEUA072201
ETHAN: A Phase II Study Comparing Different Endocrine Therapies for Male Breast Cancer
Breast
Breast
Breast
II
Sharpe, Jessica
NCT05501704
VICCBRE25028
A Phase II Non-Comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients with Metastatic HER2-Negative (HER2-Low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy (TRADE DXd)
Breast
Breast
Breast
II
Abramson, Vandana
NCT06533826
VICC-ITBRE23546
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score <- 18 Breast Cancer
Breast
Breast
Breast
III
Chak, Bapsi
NCT04852887
NRGBREBR007
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-Altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
Liver
Liver
Liver
III
Heumann, Thatcher
NCT05948475
VICC-DTGIT23271
MCC21704: A Multi-Institution Study of TGFB, Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue
Multiple Cancer Types
Pediatrics,
Sarcoma
I/II
Borinstein, Scott
NCT05634369
VICCPED24617
NRG-CC015: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer---HEAL-ABC
Breast
Breast
Breast
III
Kennedy, Laura
NCT06748222
NRGBRECC015
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma.
Pediatrics
Pediatrics
Pediatrics
III
Borinstein, Scott
NCT05304585
COGARST2032
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Hematologic
Hematologic
Hematologic
III
Mohan, Sanjay
NCT06479135
VICC-DTHEM24136
